There are currently 1092 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
NCT04995523
Recruiting
This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/15/2025
Locations: Research Site, Rochester, Minnesota
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
RA-PRO PRAGMATIC TRIAL
NCT04692493
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Rheumatoid Arthritis
Register for Updates
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
NCT06393712
Recruiting
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional saf... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/15/2025
Locations: Clinical Trial Site, Rochester, Minnesota
Conditions: Cerebral Amyloid Angiopathy
Register for Updates
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934
Recruiting
The goal of this study is to learn if GS-1427 is effective in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo. The primary objective of this study is to assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Ulcerative Colitis
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
07/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Rheumatic Joint Disease
Register for Updates
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06790966
Recruiting
This is a global, multi-center, Phase 3 study that is randomized 2:1, controlled, and open label to evaluate PDS0101 (Versamune + HPVMix) in combination with pembrolizumab vs. pembrolizumab monotherapy as first-line treatment in patients with unresectable recurrent or metastatic HPV16-positive HNSCC expressing programmed cell death ligand-1 (PD-L1) with combined positive score (CPS) ≥1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Register for Updates
The PEERLESS II Study
NCT06055920
Recruiting
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pulmonary Embolism
Register for Updates
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
NCT04665739
Recruiting
This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Neoplasm, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Unresectable Lung Neuroendocrine Tumor
Register for Updates
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
NCT05831176
Recruiting
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the ef... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/15/2025
Locations: Mayo Clinic Hospital Rochester, Rochester, Minnesota
Conditions: Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Register for Updates
CTSN Embolic Protection Trial
NCT06027788
Recruiting
This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/15/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Register for Updates
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
NCT06365905
Recruiting
This study evaluates if AI can be used with transvaginal ultrasound images for early detection of endometrial cancer or premalignant lesions.
Gender:
FEMALE
Ages:
55 years and above
Trial Updated:
07/15/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Endometrial Carcinoma
Register for Updates
Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
NCT05677919
Recruiting
This phase II trial studies how well pirtobrutinib and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. This study also seeks to adopt a blood test which shows a small number of cancer cells in the body after cancer treatment called minimal residual disease as a guide to determine length of treatment. Drugs used in chemotherapy, such as pirtobrutinib and venetoclax, work in different ways to stop the growth of tumor cells, either by killing th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates